Shared on31 Jul 25Fair value Increased 7.69%
The increase in Journey Medical’s consensus analyst price target to $10.50 reflects improved future earnings expectations as indicated by a higher forward P/E, despite a slight decline in net profit margin. What's in the News Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), Journey Medical’s treatment for inflammatory rosacea lesions in adults, now has pharmacy benefit coverage for 65% of U.S. commercial lives, up from 29% in May.
Shared on23 Apr 25Fair value Decreased 20%
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 0.41%
AnalystConsensusTarget has decreased revenue growth from 46.8% to 40.1%, decreased profit margin from 34.8% to 24.6%, increased future PE multiple from 5.3x to 8.7x and decreased shares outstanding growth rate from 0.1% to 0.1%.